MyBiotics is a microbiome pharmaceutical company developing live bacteria based drugs
The human body carries about 100 trillion microorganisms in the intestines, a number ten times greater than the total number of human cells in the body. The metabolic activities performed by these bacteria resemble those of an organ, leading some to liken gut bacteria to a “forgotten” organ. The microorganisms in the gut carry out important and useful functions in the host, , such as fermenting unused energy substrates, training the immune system, preventing growth of harmful and pathogenic bacteria, regulating the development of the gut, producing vitamins for the host, such as biotin, B-12 and vitamin K, and producing hormones that direct the host to store fats. Ingestion of processed foods, excessive use of antibiotics, and the sanitary customs of modern life , erodes the bacterial population, and changes its balance. This can results in overgrowth of harmful bacteria, yeasts, molds, and parasites that can be difficult to eradicate. For instance, reduction in the level of serotonin, or vitamins secreted by the gut microbiome affects our health and mood.
The importance of the gut microbiome has long been recognized, but only recently has the importance of gut bacteria imbalance been recognized as a crucial factor in various diseases and health conditions. The company’s proprietary technologies, MyCrobe and SuperDonor, allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobe and SuperDonor provide single or multi-bacterial combinations for targeted treatment, whole microbiome restoration and the first actual screening method to replace FMT microbiome transplantations.
The bacteria delivered using MyBiotics technologies are potentially capable of shifting unbalanced bacterial communities, often associated with a diseased state, to a healthy one. The bacteria in our gut evolved with us from the beginning of times. Every living creature on earth accommodates a bacterial population throughout its body.
MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population.
The company is currently focusing on an initial set of indications including C. difficle, post-antibiotic microbiome restoration and side effect reduction and anti-inflammation. All our products go through strict tests and scientific approvals. MyBiotics R&D and product development efforts are supported by a scientific team and advisory board combined with a group of leaders in the fields of Probiotics, microbiology, medical doctors and regulatory experts.